Beijing Chunlizhengda Medical Instruments Co Ltd
Beijing Chunlizhengda Medical Instruments Co Ltd designs, develops, and sells medical instruments and related products, primarily in the People's Republic of China.
Business. Beijing Chunlizhengda Medical Instruments Co Ltd (1858.HK) is a healthcare services and equipment company engaged in the medical equipment, supplies, and distribution industry. The firm operates on a product-sale revenue model, focusing on the provision of medical instruments and related supplies. Headquartered in Beijing, the company is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Beijing Chunlizhengda Medical Instruments Co Ltd (1858.HK) is a healthcare services and equipment company engaged in the medical equipment, supplies, and distribution industry. The firm operates on a product-sale revenue model, focusing on the provision of medical instruments and related supplies. Headquartered in Beijing, the company is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.
The company maintains a strong liquidity position, with a current ratio of 5.2, indicating a robust ability to meet short-term obligations. Free cash flow for the period was CNY 236.6 million, while operating cash flow was CNY 404.8 million, suggesting healthy cash generation from operations. The company is effectively funded through equity, with a debt-to-equity ratio of 0.0, and long-term debt of only CNY 3.8 million.
Profitability metrics show a return on equity (ROE) of 9.13% and a return on assets (ROA) of 7.44%, both of which are strong indicators of efficient capital use and asset management. The gross profit margin of 62.5% (CNY 653.4 million gross profit on CNY 1.05 billion revenue) and an operating margin of 28.9% (CNY 302.2 million operating income) suggest the company is effectively managing its production and operational costs.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification beyond the People's Republic of China. This concentration may expose the company to regional economic or regulatory risks, though the lack of segment or geographic breakdown in the financials limits further analysis.
Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or contraction indicated in the outlook. The capital expenditure of CNY -59.1 million suggests a reduction in investment in physical assets, which may reflect a shift toward optimizing existing operations rather than expansion.
The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could pose a challenge in the event of unexpected cash flow disruptions. However, the absence of significant debt and the strong equity base mitigate the dilution risk.
Recent analyst estimates suggest a generally positive outlook, with a mean price target of CNY 20.54 and a mean recommendation of 1.50 (on a scale from 1=strong buy to 5=strong sell). The consensus includes one strong-buy and one buy recommendation, with no holds or negative ratings. No recent filings or transcripts were provided to indicate material changes in the company's operations or strategy.
- The company has a strong liquidity position with a current ratio of 5.2 and positive free cash flow of CNY 236.6 million.
- ROE of 9.13% and ROA of 7.44% indicate efficient use of equity and assets.
- The company is debt-free, with a debt-to-equity ratio of 0.0 and minimal long-term debt.
- Analysts have a generally positive outlook, with a mean price target of CNY 20.54 and a mean recommendation of 1.50.
- Revenue is concentrated in a single business segment and geographic region, which may increase exposure to regional risks.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,88 |
| Revenue | —no estimate | —no estimate | 1,3B CNY |
| Operating income | —no estimate | —no estimate | 364,0M CNY |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Beijing Chunlizhengda Medical Instruments Co Ltd Market data — financials · 2026-05-26
- Beijing Chunlizhengda Medical Instruments Co Ltd Market data — analyst estimates · 2026-05-26